NCT05711823View on ClinicalTrials.gov

Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Aprepitant in combination with granisetron and dexamethasone

Patients with unresectable hepatocellular carcinoma will receive aprepitant in combination with granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.

DRUG

Granisetron and dexamethasone

Patients with unresectable hepatocellular carcinoma will receive granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.

All Listed Sponsors
lead

Guangxi Medical University

OTHER